相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions
Eric D. Eisenmann et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2022)
8-acetoxy-trisulfopyrene as the first activatable fluorogenic probe for add-and-read assessment of Organic anion-transporting polypeptides, OATP1B1, OATP1B3, and OATP2B1
Orsolya Ungvari et al.
FASEB JOURNAL (2021)
Interaction of the FLT3 Inhibitor Gilteritinib with Xenobiotic Uptake Transporters
Dominique Garrison et al.
FASEB JOURNAL (2021)
Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1
Mingqing Chen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Venetoclax in acute myeloid leukemia - current and future directions
Curtis Lachowiez et al.
LEUKEMIA & LYMPHOMA (2020)
Development and validation of a sensitive UHPLC-MS/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies
Eric D. Eisenmann et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors
Dominique A. Garrison et al.
PHARMACEUTICS (2020)
Regulatory Recommendations for Calculating the Unbound Maximum Hepatic Inlet Concentration: A Complicated Story with a Surprising and Happy Ending
Andrew Parkinson
DRUG METABOLISM AND DISPOSITION (2019)
Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies
Hiroto Inaba et al.
CLINICAL CANCER RESEARCH (2019)
Venetoclax for AML: changing the treatment paradigm
Daniel A. Pollyea et al.
BLOOD ADVANCES (2019)
Mechanistic Physiologically Based Pharmacokinetic Modeling of the Dissolution and Food Effect of a Biopharmaceutics Classification System IV Compound-The Venetoclax Story
Arian Emami Riedmaier et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2018)
Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors
Suresh K. Agarwal et al.
ADVANCES IN THERAPY (2018)
Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
Randy A. Taplitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Clinical Pharmacokinetics and Pharmacodynamics of Micafungin
Roeland E. Wasmann et al.
CLINICAL PHARMACOKINETICS (2018)
Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites
Hong Liu et al.
DRUG METABOLISM AND DISPOSITION (2017)
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Antifungal prophylaxis in newly diagnosed AML patients-Adherence to guidelines and feasibility in a real life setting
Sophie Berking et al.
MYCOSES (2017)
Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects
Takao Yamazaki et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects
Takao Yamazaki et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma
Suresh K. Agarwal et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments
Suresh K. Agarwal et al.
CLINICAL THERAPEUTICS (2017)
Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP
Vincent J. C. Lempers et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients
Vycke Yunivita et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)
Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study
Suresh K. Agarwal et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
An update on the role of intestinal cytochrome P450 enzymes in drug disposition
Fang Xie et al.
ACTA PHARMACEUTICA SINICA B (2016)
Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters
Lydia M. M. Vermeer et al.
DRUG METABOLISM AND DISPOSITION (2016)
Safety and Pharmacokinetics of Isavuconazole as Antifungal Prophylaxis in Acute Myeloid Leukemia Patients with Neutropenia: Results of a Phase 2, Dose Escalation Study
Oliver A. Cornely et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection
Elizabeth M. Sherman et al.
CLINICAL THERAPEUTICS (2015)
The Nonspecific Binding of Tyrosine Kinase Inhibitors to Human Liver Microsomes
Kushari Burns et al.
DRUG METABOLISM AND DISPOSITION (2015)
Pharmacokinetics of Cobicistat Boosted-Elvitegravir Administered in Combination With Rosuvastatin
Joseph M. Custodio et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide
Eric I. Zimmerman et al.
CLINICAL CANCER RESEARCH (2013)
Steady-state pharmacokinetics and metabolism of voriconazole in patients
Marcus J. P. Geist et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
OATP1B1 Polymorphism as a Determinant of Erythromycin Disposition
C. S. Lancaster et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers
Gopal Krishna et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition
Laura B. Ramsey et al.
GENOME RESEARCH (2012)
PHARMACOLOGY AND METABOLISM OF ANIDULAFUNGIN, CASPOFUNGIN AND MICAFUNGIN IN THE TREATMENT OF INVASIVE CANDIDOSIS - REVIEW OF THE LITERATURE
G. Kofla et al.
EUROPEAN JOURNAL OF MEDICAL RESEARCH (2011)
Impact of OATP transporters on pharmacokinetics
A. Kalliokoski et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Targeted disruption of murine organic anion-transporting polypeptide 1b2 (oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin
Hani Zaher et al.
MOLECULAR PHARMACOLOGY (2008)
Antifungal agents - clinical pharmacokinetics and drug interactions
Hans-Peter Lipp
MYCOSES (2008)
Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo
I. E. Templeton et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism
Antonius E. van Herwaarden et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers
CJL la Porte et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Single- and multiple-dose pharmacokinetics of caspofungin in healthy men
JA Stone et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
分享论文
